

When requesting Apokyn® (apomorphine), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication¹

- Apokyn® (apomorphine) is indicated for the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) with advanced Parkinson’s disease.

Approved Off-label Compendial use²

- No off-label uses meet evidence standards

Coverage Guidelines

Parkinson’s disease

The individual must meet **all** of the following criteria for approval:

- Diagnosis of Parkinson’s disease¹
- Experiencing acute, intermittent hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes)¹
- Absence of ALL of the following contraindications:
 - Concomitant use with 5-Hydroxytryptamine type 3 (5HT₃) antagonists, including any of the following¹:
 - o ondansetron
 - o granisetron
 - o dolasetron
 - o palonosetron
 - o alosetron

Approval duration: 12 months

Additional Information for Prescribers¹

Our prescribers are alerted to the following safety concerns as educational points/reminders:

- Begin antiemetic therapy with trimethobenzamide 3 days prior to initiation Apokyn® (apomorphine) and continue for at least the first 2 months of treatment
- Apokyn® (apomorphine) should not be administered intravenously due to the potential of thrombus formation and pulmonary embolism

- Concomitant use of antiemetics with anti-dopaminergic actions (e.g., haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide) have the potential to worsen the symptoms in patients with Parkinson's disease and should be avoided

References

1. Apokyn® prescribing information. Louisville, KY: US WorldMeds, LLC: July 2014.
2. Klasco RK (Ed): DRUGDEX® system. Thomson Micromedex, Greenwood Village, CO. Accessed February 10, 2017. <https://www.micromedexsolutions.com>.